The RIQAS CYFRA 21-1 EQA programme is designed to cover the analysis of CYFRA 21-1 in clinical laboratories when monitoring the response to treatment of cancers such as non-small cell lung carcinoma, cervical, breast and bladder cancer.
- Lyophilised samples
- Monthly reporting
- Testing covers the full range of clinically relevant decision levels
- Submit results and view reports online via RIQAS.net
- 12 month subscription
Not accredited to ISO/IEC 17043
- CYFRA 21-1 (Cytokeratin 19)
Please note, product availability may vary country to country.